AXON stock forecast, quote, news & analysis
Axon Enterprise Inc is building a public safety operating system by integrating a suite of hardware devices and cloud software solutions... Show more
Axon Enterprise (AXON) Stock Analysis: AI-Powered Public Safety Surge
Key Takeaways
- Axon Enterprise reported Q4 2025 revenue of $797 million, up 39% year-over-year, beating estimates.
- Adjusted EPS of $2.15 exceeded consensus by 34%, driving an initial 18% stock surge post-earnings.
- Company guided 27%-30% revenue growth for 2026, targeting $3.53-$3.61 billion, with long-term $6 billion goal by 2028.
- Analysts maintain a Strong Buy consensus, with average price target around $748-$768 implying 30%+ upside.
- Bookings hit $7.4 billion annually, fueled by AI software, TASER 10, and international expansion, though softer Q4 bookings tempered gains.
- Stock remains volatile, down from 52-week high of $886 but up 18% in recent weeks amid positive guidance.
Current Market Snapshot
Axon Enterprise (AXON) stock has navigated volatility in recent trading sessions, reflecting robust demand for its public safety ecosystem amid broader market fluctuations. Shares surged sharply following blowout quarterly results, underscoring strength in AI-enhanced software and hardware like body cameras and conducted energy devices. Elevated trading activity highlights investor focus on the company's transition to recurring revenue streams, with annual recurring revenue climbing significantly. While pullbacks from prior peaks persist due to sector rotations and profitability concerns, consensus remains optimistic on long-term growth in cloud services and international markets. The stock trades well below its yearly high but above key supports, positioning it for potential momentum in the latest market cycle.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds of agents that analyze and trade thousands of tickers across diverse strategies. These bots employ advanced Financial Learning Models to adapt to market conditions, delivering standout results like annualized returns up to 227%, win rates of 70-80%, and profit factors exceeding 2.5 in sectors such as semiconductors, technology, and ETFs. Others target aerospace & defense with 68-83% win rates and up to 125% returns, or volatility plays boasting 75-95% win rates and profit factors over 12.5. Spanning short-term momentum, high-frequency 5-15 minute trades, and longer-term trends, each bot varies in timeframe, risk profile, and focus—some excelling in countertrend IPOs with 158% gains. This dynamic selection highlights bots best suited to current volatility and rotations. Investors can explore these audited performances and subscribe to promising ones for automated trading.
Recent Developments Driving AXON Price Action
Axon Enterprise (AXON), the leading provider of body cameras, TASER devices, and AI-driven public safety software, experienced significant price swings in recent weeks tied to its fiscal Q4 2025 earnings and forward guidance. On February 24, 2026, the company released results showing revenue of $797 million, a 39% year-over-year increase that surpassed estimates of $755 million. Adjusted non-GAAP EPS reached $2.15, beating consensus by $0.55 or 34%, fueled by 40% growth in software and services to $343 million and strong hardware sales including TASER 10 and Axon Body 4.
The earnings triggered an immediate after-hours jump of over 15%, extending to nearly 18% the next day as shares hit intraday highs around $551. Full-year 2025 revenue totaled $2.8 billion, up 33%, with annual recurring revenue rising 35% to $1.3 billion and bookings surging 46% to $7.4 billion. International and corrections markets delivered record results, while new AI products like Axon Assistant and counter-drone systems contributed over $1 billion in bookings.
Guidance further bolstered sentiment: 2026 revenue projected at 27-30% growth ($3.53-3.61 billion) with 25.5% adjusted EBITDA margins, and a 2028 target of $6 billion revenue at 28% margins. However, softer-than-expected Q4 bookings growth introduced caution, leading to some profit-taking and consolidation around $550-$580 levels. Insider sales by executives also added mild pressure.
Analyst reactions were overwhelmingly positive, maintaining a Strong Buy consensus from 18-20 firms. TD Cowen raised its target to $950, while others like Goldman Sachs ($720), Piper Sandler ($690), and UBS ($570) adjusted downward modestly but kept Buy/Overweight ratings, citing AI momentum and ecosystem stickiness. Average targets cluster at $748, implying substantial upside. Broader factors included SaaS sector rotations earlier pulling shares from $886 highs, but earnings reaffirmed fundamentals amid defense tech tailwinds. Overall, these developments linked directly to price surges on beats and guidance, with volatility from bookings nuance and macro rotations.
2026 Outlook and Key Factors to Monitor
Axon Enterprise enters 2026 with strong visibility from 27-30% revenue growth guidance, driven by its public safety platform's expansion into AI, cloud software, and hardware integrations. Key themes include scaling annual recurring revenue beyond $1.3 billion via premium offerings like Axon Assistant for real-time insights and virtual reality training, alongside counter-drone and 911 ecosystem growth. International markets, where body camera adoption lags the U.S., represent a major opportunity, complemented by corrections and justice sector penetration.
Risks to track encompass execution on $185-215 million capex for R&D and facilities, potential margin pressure from stock-based compensation ($590-620 million), and free cash flow conversion amid investments. Regulatory scrutiny on AI in law enforcement and competitive dynamics in drones or body cams could influence sentiment. Macro factors like public sector budgets and defense spending trends remain pivotal. Opportunities lie in $14.4 billion future bookings backlog, 125% net revenue retention, and adjacent markets like private security. Balanced monitoring of quarterly bookings acceleration, AI product adoption rates, and international wins will shape trajectory toward 2028's $6 billion ambition.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
Momentum Indicator for AXON turns positive, indicating new upward trend
AXON saw its Momentum Indicator move above the 0 level on February 19, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned positive. In of the 81 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for AXON just turned positive on February 19, 2026. Looking at past instances where AXON's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .
AXON moved above its 50-day moving average on February 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in of 378 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for AXON moved out of overbought territory on March 04, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for AXON crossed bearishly below the 50-day moving average on February 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AXON broke above its upper Bollinger Band on March 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AXON entered a downward trend on February 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.368) is normal, around the industry mean (9.872). AXON has a moderately high P/E Ratio (383.503) as compared to the industry average of (95.729). AXON's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.094). Dividend Yield (0.000) settles around the average of (0.015) among similar stocks. P/S Ratio (17.153) is also within normal values, averaging (11.103).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company
Industry AerospaceDefense